Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo)
is one of the most used anthracyclines in the treatment of many tumors, but the development …

Oncology has seen growing use of newly developed targeted therapies. Although this has
resulted in dramatic improvements in progression-free and overall survival, challenges in …

Carfilzomib (CFZ) is a proteasome inhibitor approved for relapsed/refractory multiple
myeloma (MM) but its clinical use is limited by cardiovascular toxicity. The mechanisms of …

Obesity is a global pandemic that has been associated with the development of breast,
endometrial, large intestine, renal, esophageal, and pancreatic cancer. Obesity is also …

Myocardial protection against ischemia/reperfusion injury (IRI) is mediated by various
ligands, activating different cellular signaling cascades. These include classical cytosolic …

Proteasome inhibitors such as bortezomib and carfilzomib induce apoptosis and are a
cornerstone in the treatment of relapsed or refractory multiple myeloma. However, concerns …

Background: Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory
multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena. We …

Oncologic patients are subjected to four major treatment types: surgery, radiotherapy,
chemotherapy, and immunotherapy. All nonsurgical forms of cancer management are …

Abstract Background and Purpose Cancer therapy‐related cardiovascular adverse events
(CAEs) in presence of comorbidities, are in the spotlight of the cardio‐oncology guidelines …

Diabetes mellitus (DM) has attained the status of a global pandemic. Cardiovascular
disease (CV) was the leading cause of morbidity in people with type 2 DM, however, a …